



University of Groningen

Authors' response

Fattahi, Fatemeh; Volbeda, Franke; Broekema, Martine; Lodewijk, Monique E; Hylkema, Machteld; Reddel, Helen K; Timens, Willem; Postma, Dirkje S.; ten Hacken, Nick H.T.

Published in: Thorax

DOI:

10.1136/thoraxjnl-2012-203023

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version Publisher's PDF, also known as Version of record

Publication date:

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Fattahi, F., Volbeda, F., Broekema, M., Lodewijk, M. E., Hylkema, M. N., Reddel, H. K., ... ten Hacken, N. H. T. (2013). Authors' response: to Person C primary lysis/necrosis of eosinophils and clinical control of asthma. Thorax, 68(3), 295-296. DOI: 10.1136/thoraxjnl-2012-203023

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 10-02-2018

Authors' response

We have read with great interest the comments by Dr Persson¹ on our recent paper in Thorax,2 in which we showed that clinical control of asthma associated significantly with lower numbers of activated eosinophils in the bronchial wall, yet only weakly with sputum eosinophils. As the number of eosinophils in biopsies did not associate with clinical control of asthma, we speculated that activation of eosinophils (measured as eosinophil protein X (EXP)immunopositive pixels per area) in bronchial biopsies reflects the level of disease control better than the number of eosinophils itself.² As lysis of activated eosinophils and degranulation of toxic eosinophil proteins may damage the surrounding tissue,³ Persson wondered whether EPX immunopositivity in our biopsies associated with epithelial fragility, particularly in uncontrolled asthma.

In line with Persson's hypothesis, the percentage of intact epithelium correlated negatively with EPX immunopositivity (Spearman's r=-0.30, p=0.016), whereas there was no significant correlation with the number of eosinophils in bronchial biopsies (Spearman's r=-0.12, p=0.35) (figure 1). This was not due to effects of current smoking, which is associated with increased epithelial cell proliferation, goblet cell hyperplasia, as well as with reduced eosinophil numbers in bronchial biopsies in asthma,4 since we excluded current smokers from our analysis. An additional regression model adjusted for inhaled corticosteroid use and atopy confirmed that loss of epithelial integrity and higher EPX immunopositivity are significantly associated with uncontrolled asthma, yet not with numbers of airway wall eosinophils (data not shown).

Another question from Persson's letter was whether free granules locate in close proximity of denuded epithelium. Unfortunately, this 'geographical' relationship is very difficult to quantify in a reliable way. Moreover, we believe this specific question could be better investigated prospectively using an allergen provocation model; collecting blood, biopsies and sputum at regular time points; similar to what has been done in the past by Aalbers et al. In our existing dataset, the dynamics of transepithelial migration of eosinophils⁶ (tissue-lumen correlations) cannot be investigated in a reliable way.

In conclusion, our statistical analysis supports Persson's hypothesis that ongoing lysis of activated eosinophils contributes to uncontrolled asthma. Our previous

Thorax March 2013 Vol 68 No 3 295

PostScript

Figure 1 Correlation between percentage of intact epithelium and eosinophil activation assessed by EPX immunopositivity (panel A) and number of eosinophils (panel B) in bronchial biopsies from non-smoking asthmatics. Open dots: controlled asthma (n=36), solid dots: uncontrolled asthma (n=29). Significant correlation between EPX immunopositivity and % intact epithelium in panel A (Spearman's r= -0.30, p=0.016). Subjects with uncontrolled asthma have less intact epithelium and more EPX immunopositivity (panel A).

publication and our current analyses support the notion that loss of epithelial integrity may serve an important role in this respect, since it is independently associated with loss of asthma control.

Fatemeh Fattahi, ^{1,2,3} Franke Volbeda, ^{1,3,4} Martine Broekema, ^{2,3} Monique E Lodewijk, ^{2,3} Machteld N Hylkema, ^{2,3} Helen K Reddel, ⁵ Wim Timens, ^{2,3} Dirkje S Postma, ^{1,3} Nick H T ten Hacken ^{1,3}

¹Department of Pulmonology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

²Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands ³Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands ⁴Pulmonary Rehabilitation Centre Beatrixoord, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands ⁵Woolcock Institute of Medical Research and University of Sydney, Sydney, Australia

Correspondence to Dr Nick H T ten Hacken, Department of Pulmonology, University of Groningen, University Medical Center Groningen, PO Box 30001, Groningen 9700 RB, The Netherlands; n.h.t.ten.hacken@umcg.nl

Contributors FF and NtH performed the analyses and wrote the answer. HKR, DSP, WT and MNH gave comments and revised the letter. All authors reviewed the final version.

Funding None.

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.


To cite Fattahi F, Volbeda F, Broekema M, *et al. Thorax* 2013;**68**:295–296.


Received 19 November 2012 Accepted 22 November 2012 Published Online First 19 December 2012



► http://dx.doi.org/10.1136/thoraxjnl-2012-202995

Thorax 2013;**68**:295–296. doi:10.1136/thoraxjnl-2012-203023





REFERENCES

- Persson C. Primary lysis/necrosis of eosinophils and clinical control of asthma. *Thorax* 2012. doi:10.1136/ thoraxinl-2012-202955
- Volbeda F, Broekema M, Lodewijk ME, et al. Clinical control of asthma associates with measures of airway inflammation. Thorax 2013;68:19–24.
- 3 Persson CG, Erjefalt JS. Eosinophil lysis and free granules: an in vivo paradigm for cell activation and drug development. *Trends Pharmacol Sci* 1997;18:117–123.
- 4 Fattahi F, Hylkema MN, Melgert BN, et al. Smoking and nonsmoking asthma: differences in clinical outcome and pathogenesis. Expert Rev Respir Med 2011;5:93–105.
- 5 Aalbers R, de Monchy JG, Kauffman HF, et al. Dynamics of eosinophil infiltration in the bronchial mucosa before and after the late asthmatic reaction. Eur Respir J 1993;6:840–7.
- 5 Persson C, Uller L. Transepithelial exit of leucocytes: inflicting, reflecting or resolving airway inflammation? Thorax 2010;65:1111–15.

296 Thorax March 2013 Vol 68 No 3



Authors' response

Fatemeh Fattahi, Franke Volbeda, Martine Broekema, Monique E Lodewijk, Machteld N Hylkema, Helen K Reddel, Wim Timens, Dirkje S Postma and Nick H T ten Hacken

Thorax 2013 68: 295-296 originally published online December 19, 2012 doi: 10.1136/thoraxjnl-2012-203023

Updated information and services can be found at: http://thorax.bmj.com/content/68/3/295.2

These include:

References

This article cites 6 articles, 4 of which you can access for free at: http://thorax.bmj.com/content/68/3/295.2#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/